Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer
Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib (ABT-888) in patients with pancreas adenocarcinoma (PDAC) harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Both study arms were initially considered to be experimental arms, says O'Reilly. The investigators observed a very high response in both groups. The response rates in the triplet arm were higher than in the doublet arm, but the difference was not statistically significant. The progression-free survival was 10 months in both arms and there was also a signal of an overall survival benefit across arms, which was 15 months and 16 months, respectively.
In a pooled analysis that included all patients in the study, one-third lived 2 years following treatment and 20% lived 3 years. These data suggest that there is a tail on the curve for this subset of patient with pancreatic cancer.
